HUTCHMED operates primarily through two business segments: Oncology/Immunology and Other Ventures. The core Oncology/Immunology segment drives the company's growth through the research, development, and commercialization of novel therapeutics, including approved cancer drugs like fruquintinib, savolitinib, and surufatinib. The Other Ventures segment historically included a prescription drug distribution business in China, though the company recently divested a significant portion of this to focus on its core pipeline. HUTCHMED leverages its internal R&D capabilities to discover small molecule and antibody-targeted therapy conjugate (ATTC) candidates. The company maintains strategic global partnerships with major pharmaceutical firms such as AstraZeneca, Takeda, and Eli Lilly to support the international clinical development and commercialization of its products.
